1. Foà R, Bassan R, Vitale A, et al. Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. N Engl J Med 2020;383:1613-23. 2. Chiaretti S, Leoncin M, Elia L et al. Comparison ...
另外,根据在2023年ASCO、ASH年会上陆续公布的3期PhALLCON试验(NCT03589326)结果显示,与伊马替尼相比, Ph+ ALL患者在降低化疗强度的基础上加用第三代TKI普纳替尼(Ponatinib)可提高诱导治疗结束时MRD阴性CR率[2, 3]。 直面挑战,Ph+ A...
Aims . To compare the efficacy of the combination of ponatinib followed by blinatumomab with that reported with dasatinib followed by blinatumomab for the management of newly diagnosed adult Ph+ ALL patients. Patients and Methods . From September 2021 to July 2023, 74 patients have been enrolled ...
用于治疗初诊的费城染色体阳性(Ph+)慢性髓系白血病(CML)处于慢性期患者。 帕纳替尼Ponatinib 对其他TKI类药物耐药或不耐受的慢性期、加速期或急变期的CML成人患者,对其他TKI类药物耐药或不耐受的费城染色体阳性的急性淋巴细胞白血病,用于T315I阳性的慢性期、加速期或急变期成人CML患者或T315I阳性的Ph+的ALL 限制使用...
帕纳替尼Ponatinib 对其他TKI类药物耐药或不耐受的慢性期、加速期或急变期的CML成人患者,对其他TKI类药物耐药或不耐受的费城染色体阳性的急性淋巴细胞白血病,用于T315I阳性的慢性期、加速期或急变期成人CML患者或T315I阳性的Ph+的ALL 限制使用:不被用于治疗新诊断的慢性期CML ...
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016;91:1206–14. 10. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia ...
We found that the muta- tion confers moderate resistance to ponatinib, as observed in the patient, as well as to imatinib and nilotinib. In con- trast, BCR::ABL1SLLRD Ba/F3 cells remain highly sensitive to dasatinib. Unexpectedly, the insertion also conferred resistance to asciminib, ...
The dual class SRC/ABL inhibitor dasatinib25 and the third-generation ABLi ponatinib26 were 10- to 100-fold more potent against ABL-class alterations, with IC50 values of 0.8 to 2 nM. The ABL1-specific inhibitor, bosutinib,27 was effective only against Ba/F3 cells expressing RCSD1-ABL1 ...
Ponatinib has substantial activity and is generally well tolerated in heavily pretreated patients with chronic myeloid leukemia CML and Philadelphia chromosomepositive acute lymphoblastic leukemia Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I BCRABL mutation.Bryant Furlo...
贝林妥欧单抗联合Ponatinib的无化疗方案在新诊断以及复发/难治性Ph+ ALL患者中显示出良好的疗效和安全性,为患者带来较高完全分子学缓解率。特别是作为一线治疗用于新诊断Ph+ ALL患者时,该方案可避免高强度化疗带来的不良反应,并能减少患者...